Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 2, 2005, Pages 373-379

  Kirk, Gregory D ^a,b   Turner, Paul C ^d   Gong, Yunyun ^d   Lesi, Olufunmilayo A ^b   Mendy, Maimuna ^c   Goedert, James J ^a   Hall, Andrew J ^e   Whittle, Hilton ^c   Hainaut, Pierre ^f   Montesano, Ruggero ^f   Wild, Christopher P ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Gambia Hepatitis Intervention Study   (Gambia)

^c MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^d UNIVERSITY OF LEEDS   (United Kingdom)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; DNA; GLUTATHIONE TRANSFERASE;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DIETARY INTAKE; DNA ADDUCT; DNA REPAIR; ENDEMIC DISEASE; ENVIRONMENTAL FACTOR; ENZYME METABOLISM; EXPOSURE; FEMALE; GAMBIA; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PEANUT; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; AFLATOXINS; CARCINOMA, HEPATOCELLULAR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; ENVIRONMENTAL EXPOSURE; EPOXIDE HYDROLASES; FEMALE; GAMBIA; GENOTYPE; GLUTATHIONE TRANSFERASE; HEPATITIS B; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 20944449802     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0161     Document Type: Article

References (47)

1. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997; 6:387-400.
2. Bah E, Parkin DM, Hall AJ, Jack AD, Whittle H. Cancer in the Gambia: 1988-97. Br J Cancer 2001;4:1207-14.
3. Montesano R, Hainaut P, Wild CP. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst 1997;89:1844-51.
4. Vall Mayans M, Hall AJ, Inskip HM, et al. Risk factors for transmission of hepatitis B virus to Gambian children. Lancet 1990;336:1107-9.
5. Whittle H, Inskip H, Bradley AK, et al. The pattern of childhood hepatitis B infection in two Gambian villages. J Infect Dis 1990;161:1112-5.
6. Wild CP, Jiang YZ, Allen SJ, Jansen LA, Hall AJ, Montesano R. Aflatoxin-albumin adducts in human sera from different regions of the world. Carcinogenesis 1990;11:2271-4.
7. Wild CP, Hudson GJ, Sabbioni G, et al. Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in the Gambia, West Africa. Cancer Epidemiol Biomarkers Prev 1992;1:229-34.
8. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res 2000;462:381-93.
9. Wild CP, Law GR, Roman E. Molecular epidemiology and cancer: promising areas for future research in the post-genomic era. Mutat Res 2002;499:3-12.
10. Wild CP, Turner PC. The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 2002;17:471-81.
11. Guengerich FP, Johnson WW, Shimada T, Ueng YF, Yamazaki H, Langouet S. Activation and detoxication of aflatoxin B1. Mutat Res 1998;402:121-8.
12. Johnson WW, Ueng YF, Widersten M, et al. Conjugation of highly reactive aflatoxin B1 exo-8,9-epoxide catalyzed by rat and human glutathione transferases: estimation of kinetic parameters. Biochemistry 1997;36:3056-60.
13. Tiemersma EW, Omer RE, Bunschoten A, et al. Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2001;10:785-91.
14. Bian JC, Shen FM, Shen L, et al. Susceptibility to hepatocellular carcinoma associated with null genotypes of GSTM1 and GSTT1. World J Gastroenterol 2000;6:228-30.
15. Yu MW, Chiu YH, Chiang YC, et al. Plasma carotenoids, glutathione S-transferase M1 and T1 genetic polymorphisms, and risk of hepatocellular carcinoma: independent and interactive effects. Am J Epidemiol 1999;149: 621-9.
16. Sun CA, Wang LY, Chen CJ, et al. Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. Carcinogenesis 2001;22:1289-94.
17. Chen CJ, Yu MW, Liaw YF, et al. Chronic hepatitis B carriers with null genotypes of glutathione S-transferase M1 and T1 polymorphisms who are exposed to aflatoxin are at increased risk of hepatocellular carcinoma. Am J Hum Genet 1996;59:128-34.
18. Johnson WW, Yamazaki H, Shimada T, Ueng YF, Guengerich FP. Aflatoxin B1 8,9-epoxide hydrolysis in the presence of rat and human epoxide hydrolase. Chem Res Toxicol 1997;10:672-6.
19. Kelly EJ, Erickson KE, Sengstag C, Eaton DL. Expression of human microsomal epoxide hydrolase in Saccharomyces cerevisiae reveals a functional role in aflatoxin B1 detoxification. Toxicol Sci 2002;65:35-42.
20. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 1994;3:421-8.
21. McGlynn KA, Rosvold EA, Lustbader ED, et al. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci U S A 1995;92:2384-7.
22. Sonzogni L, Silvestri L, De Silvestri A, et al. Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology 2002;36:195-201.
23. McGlynn KA, Hunter K, LeVoyer T, et al. Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. Cancer Res 2003;63:4594-601.
24. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts. Glycophorin A variant frequency. Cancer Res 1999;59:2557-61.
25. Kirk GD, Camus-Randon AM, Mendy M, et al. Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from the Gambia. J Natl Cancer Inst 2000;92:148-53.
26. Kirk GD, Lesi OA, Mendy M, et al. The Gambia Liver Cancer Study: infection with hepatitis B and C and the risk of hepatocellular carcinoma in West Africa. Hepatology 2004;39:211-9.
27. Pemble S, Schroeder KR, Spencer SR, et al. Human glutathione S-transferase θ (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994;300:271-6.
28. Wild CP, Fortuin M, Donate F, et al. Aflatoxin, liver enzymes, and hepatitis B virus infection in Gambian children. Cancer Epidemiol Biomarkers Prev 1993;2:555-61.
29. Allen SJ, Wild CP, Wheeler JG, et al. Aflatoxin exposure, malaria and hepatitis B infection in rural Gambian children. Trans R Soc Trop Med Hyg 1992;86:426-30.
30. Wild CP, Yin F, Turner PC, et al. Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. Int J Cancer 2000;86:1-7.
31. Turner PC, Mendy M, Whittle H, Fortuin M, Hall AJ, Wild CP. Hepatitis B infection and aflatoxin biomarker levels in Gambian children. Trop Med Int Health 2000;5:837-41.
32. Hudson GJ, Wild CP, Zarba A, Groopman JD. Aflatoxins isolated by immunoaffinity chromatography from foods consumed in the Gambia, West Africa. Nat Toxins 1992;1:100-5.
33. Shimoda R, Nagashima M, Sakamoto M, et al. Increased formation of oxidative DNA damage, 8-hydroxydeoxyguanosine, in human livers with chronic hepatitis. Cancer Res 1994;54:3171-2.
34. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998;58:604-8.
35. Divine KK, Gilliland FD, Crowell RE, et al. The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. Mutat Res 2001;461:273-8.
36. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarskers Prev 2002;11: 1513-30.
37. Yu MW, Yang SY, Pan IJ, et al. Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 2003;95:1485-8.
38. Chen SY, Chen CJ, Tsai WY, et al. Associations of plasma aflatoxin B1-albumin adduct level with plasma selenium level and genetic polymorphisms of glutathione S-transferase M1 and T1. Nutr Cancer 2000;38:179-85.
39. Wilson MH, Grant PJ, Hardie LJ, Wild CP. Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. Faseb J 2000;14:791-6.
40. Lebailly P, Willett EV, Moorman AV, et al. Genetic polymorphisms in microsomal epoxide hydrolase and susceptibility to adult acute myeloid leukaemia with defined cytogenetic abnormalities. Br J Haematol 2002;116: 587-94.
41. Guengerich FP, Johnson WW, Ueng YF, Yamazaki H, Shimada T. Involvement of cytochrome P450, glutathione S-transferase, and epoxide hydrolase in the metabolism of aflatoxin B1 and relevance to risk of human liver cancer. Environ Health Perspect 1996;104:557-62.
42. Forrester LM, Neal GE, Judah DJ, Glancey MJ, Wolf CR. Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. Proc Natl Acad Sci U S A 1990;87:8306-10.
43. Wang H, Dick R, Yin H, et al. Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry 1998;37:12536-45.
44. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
45. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-9.
46. Kirk GD. Hepatitis B vaccination and liver cancer. In: Stewart BW, Kleihues P., editors. World cancer report. Lyon (France): IARC Press; 2003. p. 144-47.
47. Egner PA, Wang JB, Zhu YR, et al. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc Natl Acad Sci U S A 2001;98:14601-6.